A Study to Evaluate Safety and Efficacy of PBK_M2502
Trial statusNot yet recruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age19+
SponsorPharmbio Korea Co., Ltd.
About this trial
This clinical trial was prospective, randomized, single-blind, 3-treatment arm, parallel treatment group, and active-controlled. , Multi-center, Phase 3 confirmatory clinical trial.
Eligibility criteria
Qualifiers
Patients who is informed and give a consent in voluntary
Patients who is scheduled a esophagogastroduodenoscopy and colonoscopy
BMI 19≤and<30
Disqualifiers
Patients who participate in other interventional study or had participated within 30 days before screening
Pregnant or breast-feeding women who do not want to stop breast-feeding
Uncontrolled hypertension
Uncontrolled diabetes
Trial design
Treatments tested in this trial
- PBK_M2502 1-Day
- PBK_M2502 2-Day
Treatment groups
110 Participants
are divided into 2 treatment groupsLocations
1Kyung Hee University Hospital at Gangdong SeoulGangdong-gu, South Korea
Sponsors and collaborators
Pharmbio Korea Co., Ltd.
Lead sponsor
Source ClinicalTrials.gov